Cardiac Marker Market Report 2026

Cardiac Marker Market Overview

• Cardiac Marker market size has reached to $12.38 billion in 2025 • Expected to grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 12.9% • Growth Driver: Cardiac Marker Market Surge Is Addressing The Growing Prevalence Of Cardiovascular Diseases • Market Trend: Specialized Biomarker To Provide Reliable Services To Their Customers • North America was the largest region in 2025.

What Is Covered Under Cardiac Marker Market?

Cardiac markers are biomolecules that are released into the bloodstream when there is damage or stress to the heart muscle. It is used to diagnose and monitor a variety of cardiac diseases, including heart attacks, angina, and heart failure. The main types of cardiac markers are troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and other biomarkers. Troponin refers to a protein that is released into the bloodstream when there is damage to the heart muscle and is commonly used to diagnose and monitor heart-related conditions. The different products of cardiac markers are reagents, instruments, chemiluminescence, immunofluorescence, immunochromatography, and ELISA. It is applied for various indications, including myocardial infarction, congestive heart failure, acute coronary syndrome, and other indications, by end users such as laboratory testing facilities, hospital labs, reference labs, contract testing labs, point-of-care testing facilities, and academic institutions.

What Is The Cardiac Marker Market Growth Forecast?

The cardiac marker market size is expected to see rapid growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing demand for faster turnaround diagnostic tests, rising integration of cardiac diagnostics with digital platforms, expansion of point-of-care testing facilities, growing adoption of advanced biomarker panels, increasing focus on precision cardiology. Major trends in the forecast period include increasing use of high-specificity cardiac marker panels, rising adoption of automated immunoassay systems, growing demand for rapid cardiac diagnosis, expansion of multiparametric testing approaches, enhanced focus on clinical decision support.

Global Cardiac Marker Market Segmentation

1) By Biomarker: Troponin, Creatine Kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, Other Biomarkers 2) By Product: Reagent, Instrument, Chemiluminescence, Immunofluorescence, Immunochromatography, ELISA 3) By Indication: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Other Indications 4) By End User: Laboratory Testing Facilities, Hospital Labs, Reference Labs, Contract Testing Labs, Point-Of-Care Testing Facilities, Academic Institutions Subsegments: 1) By Troponin: Troponin I, Troponin T, Troponin Diagnostic Kits 2) By Creatine Kinase-MB (CK-MB): CK-MB Test Kits, CK-MB Diagnostic Panels 3) By B-Type Natriuretic Peptide (BNP): BNP Test Kits, NT-ProBNP Test Kits, BNP Diagnostic Panels 4) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels 5) By Other Biomarkers: Ischemia Modified Albumin (IMA), Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP)

What Is The Driver Of The Cardiac Marker Market?

The rising prevalence of cardiac diseases is expected to propel the growth of the cardiac marker market going forward. Cardiac diseases are a group of conditions that affect the structure or operation of the heart and cause a range of medical problems. Cardiac markers are used to diagnose and monitor various cardiac conditions, including heart attacks, angina, heart failure, and other cardiovascular diseases. Thus, the demand for diagnostic tests or cardiac markers has increased. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiac diseases will fuel the cardiac marker industry's growth.

Key Players In The Global Cardiac Marker Market

Major companies operating in the cardiac marker market are Abbott Laboratories, F Hoffmann-La Roche AG, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc, bioMérieux SA, Bio-Rad Laboratories Inc, Beckman Coulter Inc, QuidelOrtho Corporation, Randox Laboratories Ltd, DiaSorin SpA, Tosoh Corporation, PerkinElmer Inc, Sysmex Corporation, Mindray Bio-Medical Electronics Co Ltd, Lepu Medical Technology Beijing Co Ltd, Trinity Biotech plc, Fujirebio Holdings Inc, Euroimmun AG, Abcam plc, Creative Diagnostics

Global Cardiac Marker Market Trends and Insights

Major companies operating in the cardiac marker market are focusing on innovative products such as high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers to drive revenues in their market. High-sensitivity troponin I (hs-cTnI) and NT-proBNP, two important cardiac biomarkers which are used to diagnose, classify, and treat. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based company that specializes in the development, manufacture, and distribution of medical equipment and solutions, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay has surpassed the minimal requirements for hs-cTn in terms of sensitivity, accuracy, and reliability in identifying myocardial damage. These new products are intended to support improved treatment for cardiovascular illnesses by giving dependable solutions that improve patient outcomes both within and beyond the context of cardiovascular illnesses.

What Are Latest Mergers And Acquisitions In The Cardiac Marker Market?

In April 2023, Abbott Laboratories, a US-based healthcare company, acquired Cardiovascular Systems Inc. for an undisclosed amount. With this acquisition, Abbott will be able to better serve patients with peripheral and coronary artery disease by offering novel and cutting-edge therapy for those with complicated cardiovascular disease. Through this acquisition, Abbott is able to expand the range of cutting-edge vascular devices it offers doctors, giving them more resources to assist patients. Cardiovascular Systems Inc. is a US-based medical technology company.

Regional Outlook

North America was the largest region in the cardiac marker market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiac Marker Market?

The cardiac marker market consists of sales of C-reactive protein (CRP) and Ischemia-modified albumin (IMA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.